This study assessed the efficacy of Eftilagimod alpha (IMP321) in conjunction with pembrolizumab for treating people who have previously untreated inoperable or metastatic NSCLC, recurring PD-(L)1 resistant NSCLC, or recurring or metastatic HNSCC. Here, CD274 is linked to head and neck squamous cell carcinoma.